Ticagrelor 90mg tablets
Requires a prescription from a doctor or prescriber
Antiplatelet drugs
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ticagrelor
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ticagrelor
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
26 branded products available
MHRA licensed products
View all licensed products for Ticagrelor on the MHRA register
Brilique 90mg tablets
Brilique 90mg tablets
Brilique 90mg tablets
Ticagrelor 90mg tablets
Ticagrelor 90mg tablets
Ticagrelor 90mg tablets
Ticagrelor 90mg tablets
Ticagrelor 90mg tablets
Ticagrelor 90mg tablets
Ticagrelor 90mg tablets
Ticagrelor 90mg tablets
Ticagrelor 90mg tablets
This is the NHS Drug Tariff indicative price used for reimbursement purposes. It may not reflect the price paid by patients or pharmacies.
View full Drug TariffSource: NHS Drug Tariff via NHSBSA. Derived from dm+d VMPP (Virtual Medicinal Product Pack) pricing data. Contains public sector information licensed under the Open Government Licence v3.0.
WHO defined daily dose (DDD)
180 mg
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via NHS dm+d BNF mapping files. Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Clinical guidelines and formulary information
British National Formulary
Ticagrelor
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(10)
Ticagrelor for the treatment of acute coronary syndromes (TA236)
Ticagrelor for preventing atherothrombotic events after myocardial infarction (TA420)
Acute coronary syndromes (NG185)
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes (TA317)
Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease (TA607)
CytoSorb for reducing risk of bleeding during cardiac surgery (MIB249)
Coronary revascularisation: Cangrelor (ESNM63)
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome (TA335)
Spartan RX point-of-care CYP2C19 test to guide treatment in acute coronary syndrome (MIB223)
CYP2C19 genotype testing to guide clopidogrel use after ischaemic stroke or transient ischaemic attack (HTG724)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
150 found
Half-life
8 hours
Mechanism
Ticagrelor is a P2Y12 receptor antagonist.
Food interactions
4 warnings
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
36%
[L14201]
A single 200mg oral dose of ticagrelor reaches a Cmax of 923ng/mL, with a Tmax of 1.5…
Half-life
8 hours
[A17595]
Protein binding
99%
[A204152][L14201]
Volume of distribution
88 L
[L14201]
Metabolism
[A17595]…
Elimination
57.8%
Clearance
0.00584L/h
[A17595]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Ticagrelor was granted EMA approval on 3 December 2010.[L14207]
Ticagrelor was granted FDA approval on 20 July 2011.[L14201]
[L14201]
Ticagrelor is also indicated to reduce the risk of a first myocardial infarction or stroke in high risk patients with coronary artery disease.
[L14201]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1237 interactions
[L14201]
Overdose can be managed through symptomatic and supportive treatment, including ECG monitoring.
[L14201][L14207]
Dialysis is not expected to remove ticagrelor from the blood due to it being highly protein bound.
[L14201]
The P2Y12 receptor couples with Gαi2 and other Gi proteins which inhibit adenylyl cyclase.[A204164] Gi mediated signalling also activates PI3K, Akt, Rap1b, and potassium channels.[A204164] The downstream effects of these activities mediate hemostasis and lead to platelet aggregation.[A204164]
Antagonism of the P2Y12 receptor reduces development of occlusive thromboses, which can reduce the risk of myocardial infarction and ischemic stroke.[A204164]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L14201]
A single 200mg oral dose of ticagrelor reaches a Cmax of 923ng/mL, with a Tmax of 1.5 hours and an AUC of 6675ng\*h/mL.
[A17595]
The active metabolite of ticagrelor reaches a Cmax of 264ng/mL, with a Tmax of 3.0 hours and an AUC of 2538ng\*h/mL.
[A17595]
[A17595]
[A204152][L14201]
[L14201]
[A17595]
Ticagrelor can be dealkylated at postition 5 of the cyclopentane ring to form the active AR-C124910XX.
[A17595]
AR-C124910XX's cyclopentane ring can be further glucuronidated or the alkyl chain attached to the sulfur can be hydroxylated.
[A17595]
Ticagrelor can also be glucuronidated or hydroxylated.
[A17595]
Ticagrelor can also be N-dealkylated to form AR-C133913XX, which is further glucuronidated or hydroxylated.
[A17595]
[A17595][L14201]
Less than 1% of the dose is recovered as the unmetabolized parent drug.
[L14201]
The active metabolite AC-C124910XX makes up 21.7% of the recovery in the feces.
[A17595]
The metabolite AR-C133913XX makes up 9.2% of the recovery in the urine and 2.7% of the recovery in the feces.
[A17595]
Other minor metabolites are predominantly recovered in the urine.
[A17595]
[A17595]
Proteins and enzymes this drug interacts with in the body
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that transport this drug across cell membranes
PMID:2897240 PMID:35970996 PMID:8898203 PMID:9038218 PMID:35507548
Catalyzes the flop of phospholipids from the cytoplasmic to the exoplasmic leaflet of the apical membrane. Participates mainly to the flop of phosphatidylcholine, phosphatidylethanolamine, beta-D-glucosylceramides and sphingomyelins .
PMID:8898203
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells PMID:2897240 PMID:35970996 PMID:9038218
Proteins that carry this drug through the body
PMID:19021548
Major calcium and magnesium transporter in plasma, binds approximately 45% of circulating calcium and magnesium in plasma (By similarity).
Potentially has more than two calcium-binding sites and might additionally bind calcium in a non-specific manner (By similarity). The shared binding site between zinc and calcium at residue Asp-273 suggests a crosstalk between zinc and calcium transport in the blood (By similarity). The rank order of affinity is zinc > calcium > magnesium (By similarity).
Binds to the bacterial siderophore enterobactin and inhibits enterobactin-mediated iron uptake of E.coli from ferric transferrin, and may thereby limit the utilization of iron and growth of enteric bacteria such as E.coli .
PMID:6234017
Does not prevent iron uptake by the bacterial siderophore aerobactin PMID:6234017
ATC B01AC24
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ticagrelor
Additional database identifiers
Drugs Product Database (DPD)
20742
ChemSpider
8047109
BindingDB
50397205
PDB
TIQ
ZINC
ZINC000028957444
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18124
GenAtlas
P2RY12
GeneCards
P2RY12
GenBank Gene Database
AF313449
GenBank Protein Database
12083902
Guide to Pharmacology
328
UniProt Accession
P2Y12_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2638
GenAtlas
CYP3A5
GeneCards
CYP3A5
GenBank Gene Database
J04813
GenBank Protein Database
181346
Guide to Pharmacology
1338
UniProt Accession
CP3A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2615
GeneCards
CYP2B6
GenBank Gene Database
M29874
GenBank Protein Database
181296
Guide to Pharmacology
1324
UniProt Accession
CP2B6_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2623
GenAtlas
CYP2C9
GeneCards
CYP2C9
GenBank Gene Database
AY341248
Guide to Pharmacology
1326
UniProt Accession
CP2C9_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:399
GenAtlas
ALB
GeneCards
ALB
GenBank Gene Database
V00494
GenBank Protein Database
28590
UniProt Accession
ALBU_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:40
GenAtlas
ABCB1
GeneCards
ABCB1
GenBank Gene Database
M14758
GenBank Protein Database
307180
Guide to Pharmacology
768
UniProt Accession
MDR1_HUMAN
Patent information
2 active patents, 8 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: